Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rebecq – page 15

1 850 clinical trials in Rebecq, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rebecq at a glance
1 850
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 850 trials in Rebecq

Open in trial search

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Obesity

Recruiting

Semaglutide for weight management in adults with obesity and binge‑eating: a study to identify who benefits

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:UZ Leuven

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Intravenous sgt-003 in Ambulatory Male Patients with Duchenne Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:SGT-003
  • Sponsor:Solid Biosciences Inc.

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Rebecq

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. This research aims to optimize medication management for individuals with functional dyspepsia and reflux-related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Medication De-prescribing Strategies

The research evaluates different approaches including on-demand usage and alternative treatments, aimed at improving patient care in primary healthcare settings.

02 Primary Care Medicine

Studies examining long-term medication management practices in primary care, with a focus on gastrointestinal disorders and symptom control. This research explores alternative treatment approaches for common digestive complaints.

  • Treatment Optimization
  • Alternative Therapy Evaluation
  • Patient-Centered Care

The research compares various therapeutic strategies to identify the most effective approach for managing chronic digestive conditions in primary care settings.

03 Clinical Therapeutics

Investigation into medication discontinuation strategies, focusing on long-term acid suppression therapy. This research evaluates the effectiveness of different approaches to reducing medication dependence while maintaining symptom control.

  • Therapeutic Alternative Assessment
  • Symptom Management
  • Treatment Efficacy Comparison

The study compares conventional dose reduction methods with newer therapeutic approaches to optimize patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.